I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU424299925US, in an envelope addressed to:

Commissioner for Patents, Washington, DC 20231, on the pate shown below.

Docket No.: 28967/37084A/US

Dated: September 26, 2002

nature:

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Alitalo et al.

Application No.: 10/046,922

Group Art Unit: 1645

Filed: January 15, 2002

Examiner: Not Yet Assigned

For:

VEGFR-3 INHIBITOR MATERIALS AND

METHODS AND PROTEINS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents Washington, DC 20231

Dear Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached Form 1449A/PTO and copies of documents cited therein are hereby submitted by Applicants for consideration in connection with the above-identified patent application.

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This statement and the Form 1449A/PTO are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). However, if it is determined that any appropriate fee is due, please charge Deposit Account Number 13-2855. A duplicate of this paper is enclosed.

Application No.: 10/046,922

Dated: September 26, 2002

Docket No.: 28967/37084A/US

Respectfully submitted,

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorneys for Applicant

